07:46 AM EDT, 04/02/2025 (MT Newswires) -- Nurix Therapeutics ( NRIX ) said Wednesday that Sanofi ( SNY ) has exclusively licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases.

The company said the target is a key regulator of inflammation and is separate from its earlier disclosed STAT6 degrader program.

Under the collaboration, Nurix said it will use its DEL-AI drug discovery platform to identify new agents that utilize E3 ligases to degrade the target.

Sanofi ( SNY ) has the right to license drug candidates resulting from the work, while Nurix has the option to co-develop and co-promote up to two products in the US after clinical proof of concept, it added.

For programs where Nurix doesn't exercise its co-development option, it will receive milestones and royalties based on global sales, the company said.

Nurix said it received a $15 million license extension fee from Sanofi ( SNY ) under its 2019 collaboration agreement, bringing the total amount to date to $105 million, and is eligible for up to $465 million in development, regulatory, and commercial milestones for each licensed program, plus royalties on future sales.

Shares of the company rose 2.5% in recent premarket activity.